Cox univariate and multivariate analyses of baseline variables predicting TFS
| Variables . | HR (95% CI) . | P . |
|---|---|---|
| Univariate analysis | ||
| iuFLCR >6 at diagnosis | 1.69 (1.06-2.69) | .017 |
| BMDex as up-front therapy | 0.36 (0.13-0.82) | .009 |
| CR after up-front therapy | 0.36 (0.18-0.64) | <.001 |
| Age, y | 1.00 (0.99-1.02) | .877 |
| BMPC, % | 1.01 (0.99-1.04) | .404 |
| BMPC >10% | 1.13 (0.67-1.92) | .644 |
| dFLC >50 mg/L | 1.44 (0.87-2.37) | .160 |
| dFLC >180 mg/L | 1.04 (0.69-1.59) | .835 |
| Heart involvement | 0.94 (0.61-1.45) | .770 |
| Cardiac stage III | 0.85 (0.50-1.47) | .570 |
| Renal stage III | 0.70 (0.30-1.60) | .398 |
| Multivariate analysis | ||
| iuFLCR >6 at diagnosis | 1.41 (0.87-2.27) | .161 |
| BMDex as up-front therapy | 0.40 (0.20-0.81) | .011 |
| CR after up-front therapy | 0.40 (0.24-0.65) | <.001 |
| Variables . | HR (95% CI) . | P . |
|---|---|---|
| Univariate analysis | ||
| iuFLCR >6 at diagnosis | 1.69 (1.06-2.69) | .017 |
| BMDex as up-front therapy | 0.36 (0.13-0.82) | .009 |
| CR after up-front therapy | 0.36 (0.18-0.64) | <.001 |
| Age, y | 1.00 (0.99-1.02) | .877 |
| BMPC, % | 1.01 (0.99-1.04) | .404 |
| BMPC >10% | 1.13 (0.67-1.92) | .644 |
| dFLC >50 mg/L | 1.44 (0.87-2.37) | .160 |
| dFLC >180 mg/L | 1.04 (0.69-1.59) | .835 |
| Heart involvement | 0.94 (0.61-1.45) | .770 |
| Cardiac stage III | 0.85 (0.50-1.47) | .570 |
| Renal stage III | 0.70 (0.30-1.60) | .398 |
| Multivariate analysis | ||
| iuFLCR >6 at diagnosis | 1.41 (0.87-2.27) | .161 |
| BMDex as up-front therapy | 0.40 (0.20-0.81) | .011 |
| CR after up-front therapy | 0.40 (0.24-0.65) | <.001 |
Cardiac stage III is defined by NT-proBNP >332 ng/L and cTnI >0.1 ng/L. Renal stage III is defined by eGFR <50 mL/min per 1.73 m2 and proteinuria >5 g/24 h.
CI, confidence interval; HR, hazard ratio.